 James Burton
Concepts (377)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 31 | 2023 | 844 | 3.790 |
Why?
| | Hepatitis C | 17 | 2021 | 215 | 2.830 |
Why?
| | Antiviral Agents | 17 | 2021 | 650 | 2.350 |
Why?
| | Hepatitis C, Chronic | 11 | 2021 | 151 | 2.280 |
Why?
| | Ribavirin | 8 | 2015 | 88 | 1.560 |
Why?
| | Hepacivirus | 11 | 2021 | 226 | 0.960 |
Why?
| | Proline | 6 | 2015 | 71 | 0.950 |
Why?
| | Protease Inhibitors | 3 | 2018 | 101 | 0.940 |
Why?
| | Kidney Transplantation | 4 | 2023 | 576 | 0.860 |
Why?
| | Liver Function Tests | 3 | 2022 | 107 | 0.840 |
Why?
| | Liver | 10 | 2023 | 1802 | 0.770 |
Why?
| | Oligopeptides | 5 | 2015 | 247 | 0.750 |
Why?
| | Interferon-alpha | 3 | 2014 | 191 | 0.750 |
Why?
| | Drug Therapy, Combination | 12 | 2018 | 963 | 0.720 |
Why?
| | Patient Selection | 3 | 2020 | 669 | 0.670 |
Why?
| | Polyethylene Glycols | 4 | 2014 | 575 | 0.660 |
Why?
| | Interferons | 4 | 2015 | 151 | 0.650 |
Why?
| | Graft Rejection | 4 | 2018 | 547 | 0.590 |
Why?
| | Living Donors | 7 | 2022 | 318 | 0.580 |
Why?
| | Recurrence | 12 | 2015 | 969 | 0.530 |
Why?
| | Liver Failure | 3 | 2016 | 85 | 0.500 |
Why?
| | Postoperative Complications | 5 | 2022 | 2230 | 0.500 |
Why?
| | Non-alcoholic Fatty Liver Disease | 3 | 2022 | 277 | 0.420 |
Why?
| | Immunocompromised Host | 1 | 2013 | 198 | 0.390 |
Why?
| | Viral Nonstructural Proteins | 2 | 2014 | 56 | 0.370 |
Why?
| | Humans | 74 | 2023 | 118053 | 0.350 |
Why?
| | Graft Survival | 4 | 2023 | 496 | 0.350 |
Why?
| | Tissue Donors | 4 | 2021 | 334 | 0.340 |
Why?
| | Middle Aged | 35 | 2022 | 27431 | 0.340 |
Why?
| | Home Care Services, Hospital-Based | 2 | 1999 | 10 | 0.330 |
Why?
| | T-Lymphocytes, Regulatory | 2 | 2008 | 356 | 0.320 |
Why?
| | Decision Support Techniques | 2 | 2018 | 365 | 0.310 |
Why?
| | Simeprevir | 2 | 2018 | 9 | 0.300 |
Why?
| | Esophageal and Gastric Varices | 1 | 2007 | 40 | 0.300 |
Why?
| | Acute Disease | 7 | 2008 | 933 | 0.290 |
Why?
| | Tissue and Organ Procurement | 2 | 2023 | 247 | 0.280 |
Why?
| | Severity of Illness Index | 5 | 2021 | 2652 | 0.280 |
Why?
| | Health Services for the Aged | 5 | 2000 | 71 | 0.270 |
Why?
| | Liver Cirrhosis | 3 | 2015 | 243 | 0.260 |
Why?
| | Reproducibility of Results | 5 | 2022 | 2855 | 0.260 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2008 | 978 | 0.260 |
Why?
| | Geriatrics | 7 | 2000 | 67 | 0.250 |
Why?
| | Cholates | 2 | 2022 | 2 | 0.250 |
Why?
| | Health Care Rationing | 1 | 2004 | 48 | 0.250 |
Why?
| | United States | 17 | 2023 | 12477 | 0.250 |
Why?
| | Male | 41 | 2021 | 57370 | 0.240 |
Why?
| | Home Care Services | 3 | 1997 | 215 | 0.240 |
Why?
| | Solitary Kidney | 1 | 2023 | 8 | 0.240 |
Why?
| | Viremia | 3 | 2021 | 127 | 0.230 |
Why?
| | Aged | 29 | 2018 | 19555 | 0.230 |
Why?
| | Cecal Neoplasms | 1 | 2003 | 1 | 0.230 |
Why?
| | Jejunoileal Bypass | 1 | 2003 | 1 | 0.230 |
Why?
| | Treatment Outcome | 15 | 2022 | 9310 | 0.230 |
Why?
| | Liver Diseases | 1 | 2006 | 282 | 0.230 |
Why?
| | Reoperation | 4 | 2007 | 554 | 0.230 |
Why?
| | Female | 39 | 2021 | 61140 | 0.220 |
Why?
| | Cholangitis | 1 | 2022 | 25 | 0.210 |
Why?
| | Transplant Recipients | 2 | 2021 | 148 | 0.200 |
Why?
| | Forecasting | 3 | 2014 | 347 | 0.200 |
Why?
| | Recombinant Proteins | 4 | 2014 | 1301 | 0.200 |
Why?
| | Cholangitis, Sclerosing | 1 | 2022 | 75 | 0.190 |
Why?
| | Liver Circulation | 1 | 2021 | 23 | 0.190 |
Why?
| | Colonoscopy | 1 | 2003 | 208 | 0.190 |
Why?
| | Nursing Homes | 2 | 1994 | 130 | 0.190 |
Why?
| | Adult | 21 | 2021 | 31227 | 0.190 |
Why?
| | Deuterium | 1 | 2021 | 77 | 0.190 |
Why?
| | Famous Persons | 1 | 2000 | 6 | 0.190 |
Why?
| | Carbon Isotopes | 1 | 2021 | 115 | 0.190 |
Why?
| | Consensus Development Conferences as Topic | 1 | 2020 | 31 | 0.180 |
Why?
| | Healthy Volunteers | 1 | 2021 | 194 | 0.180 |
Why?
| | Blood Coagulation Disorders | 1 | 2022 | 166 | 0.180 |
Why?
| | Sofosbuvir | 2 | 2021 | 52 | 0.180 |
Why?
| | Donor Selection | 1 | 2020 | 73 | 0.170 |
Why?
| | Carbamates | 2 | 2021 | 36 | 0.170 |
Why?
| | Allografts | 1 | 2020 | 133 | 0.170 |
Why?
| | Reference Values | 1 | 2021 | 764 | 0.170 |
Why?
| | Kidney | 3 | 2023 | 1351 | 0.170 |
Why?
| | Antibiotic Prophylaxis | 1 | 2020 | 99 | 0.170 |
Why?
| | Coronary Artery Disease | 2 | 2020 | 648 | 0.160 |
Why?
| | Practice Patterns, Physicians' | 2 | 2005 | 1195 | 0.160 |
Why?
| | Cohort Studies | 6 | 2018 | 5072 | 0.160 |
Why?
| | Hepatitis, Autoimmune | 1 | 2018 | 33 | 0.160 |
Why?
| | Biopsy | 2 | 2020 | 1073 | 0.160 |
Why?
| | RNA, Viral | 4 | 2015 | 567 | 0.160 |
Why?
| | Geriatric Assessment | 2 | 1997 | 182 | 0.160 |
Why?
| | Physician-Patient Relations | 3 | 2000 | 481 | 0.160 |
Why?
| | Heterocyclic Compounds, 3-Ring | 1 | 2018 | 28 | 0.160 |
Why?
| | Eligibility Determination | 2 | 1997 | 55 | 0.150 |
Why?
| | Coronary Angiography | 3 | 2020 | 311 | 0.150 |
Why?
| | Thrombolytic Therapy | 2 | 1997 | 116 | 0.150 |
Why?
| | Consensus | 1 | 2020 | 531 | 0.150 |
Why?
| | Leukocyte Count | 1 | 2018 | 304 | 0.150 |
Why?
| | Drug Interactions | 3 | 2013 | 351 | 0.150 |
Why?
| | Diagnostic Tests, Routine | 1 | 2018 | 89 | 0.150 |
Why?
| | Forkhead Transcription Factors | 2 | 2008 | 181 | 0.150 |
Why?
| | Retrospective Studies | 11 | 2022 | 12921 | 0.150 |
Why?
| | HIV Integrase Inhibitors | 1 | 2018 | 61 | 0.150 |
Why?
| | End Stage Liver Disease | 1 | 2018 | 74 | 0.150 |
Why?
| | Family Planning Policy | 1 | 2016 | 1 | 0.140 |
Why?
| | Adenocarcinoma | 1 | 2003 | 806 | 0.140 |
Why?
| | Odds Ratio | 4 | 2015 | 992 | 0.140 |
Why?
| | Health Planning | 1 | 2016 | 47 | 0.140 |
Why?
| | Public Policy | 1 | 2016 | 62 | 0.140 |
Why?
| | Long-Term Care | 1 | 2016 | 74 | 0.140 |
Why?
| | Prognosis | 5 | 2020 | 3420 | 0.140 |
Why?
| | Fibrosis | 1 | 2018 | 481 | 0.130 |
Why?
| | Population Dynamics | 1 | 2016 | 136 | 0.130 |
Why?
| | Aortic Valve Insufficiency | 1 | 2015 | 42 | 0.130 |
Why?
| | Prospective Studies | 7 | 2021 | 6443 | 0.130 |
Why?
| | Young Adult | 7 | 2021 | 10705 | 0.130 |
Why?
| | Macrocyclic Compounds | 1 | 2014 | 9 | 0.130 |
Why?
| | Time Factors | 10 | 2018 | 6362 | 0.130 |
Why?
| | Program Evaluation | 1 | 1999 | 834 | 0.130 |
Why?
| | Developing Countries | 1 | 2016 | 252 | 0.120 |
Why?
| | Genotype | 3 | 2015 | 1859 | 0.120 |
Why?
| | Homes for the Aged | 1 | 1994 | 19 | 0.120 |
Why?
| | Anilides | 1 | 2014 | 68 | 0.120 |
Why?
| | Comprehensive Health Care | 1 | 1994 | 19 | 0.120 |
Why?
| | Survival Analysis | 4 | 2018 | 1261 | 0.120 |
Why?
| | Patient Satisfaction | 1 | 1998 | 609 | 0.120 |
Why?
| | Glucocorticoids | 1 | 2018 | 546 | 0.120 |
Why?
| | Factor Xa Inhibitors | 2 | 2005 | 138 | 0.110 |
Why?
| | Transcatheter Aortic Valve Replacement | 1 | 2015 | 151 | 0.110 |
Why?
| | Serine Proteinase Inhibitors | 1 | 2013 | 35 | 0.110 |
Why?
| | Transplantation | 1 | 2013 | 25 | 0.110 |
Why?
| | Follow-Up Studies | 6 | 2016 | 4571 | 0.110 |
Why?
| | Quality of Life | 4 | 2018 | 2360 | 0.110 |
Why?
| | Pyridazines | 1 | 2013 | 50 | 0.110 |
Why?
| | Spinal Diseases | 1 | 1993 | 47 | 0.110 |
Why?
| | DEAD-box RNA Helicases | 1 | 2013 | 56 | 0.110 |
Why?
| | Myocardial Infarction | 3 | 2005 | 966 | 0.110 |
Why?
| | Multivariate Analysis | 3 | 2015 | 1468 | 0.110 |
Why?
| | Mental Health | 1 | 2018 | 565 | 0.110 |
Why?
| | Cholangiocarcinoma | 1 | 2012 | 38 | 0.100 |
Why?
| | Bile Ducts, Intrahepatic | 1 | 2012 | 53 | 0.100 |
Why?
| | Immunosuppressive Agents | 2 | 2013 | 683 | 0.100 |
Why?
| | Bile Duct Neoplasms | 1 | 2012 | 55 | 0.100 |
Why?
| | Aortic Valve Stenosis | 1 | 2015 | 296 | 0.100 |
Why?
| | Postoperative Care | 1 | 2013 | 237 | 0.100 |
Why?
| | Hepatic Insufficiency | 1 | 2010 | 4 | 0.100 |
Why?
| | Interleukins | 1 | 2013 | 242 | 0.100 |
Why?
| | Chemoradiotherapy | 1 | 2012 | 199 | 0.090 |
Why?
| | Th1 Cells | 2 | 2008 | 132 | 0.090 |
Why?
| | Preoperative Care | 1 | 2013 | 332 | 0.090 |
Why?
| | Blood Component Transfusion | 1 | 2011 | 69 | 0.090 |
Why?
| | Death Certificates | 1 | 1990 | 28 | 0.090 |
Why?
| | Autopsy | 1 | 1990 | 89 | 0.090 |
Why?
| | Aged, 80 and over | 9 | 2015 | 6533 | 0.090 |
Why?
| | Longitudinal Studies | 4 | 2016 | 2487 | 0.090 |
Why?
| | Nucleosides | 1 | 2009 | 25 | 0.090 |
Why?
| | Primary Health Care | 2 | 1993 | 1540 | 0.090 |
Why?
| | Myocardial Stunning | 1 | 2009 | 5 | 0.090 |
Why?
| | Uremia | 1 | 2009 | 18 | 0.090 |
Why?
| | Prodrugs | 1 | 2009 | 44 | 0.090 |
Why?
| | Erythrocyte Transfusion | 1 | 2011 | 183 | 0.080 |
Why?
| | RNA | 1 | 2015 | 829 | 0.080 |
Why?
| | Drug Resistance, Viral | 1 | 2009 | 98 | 0.080 |
Why?
| | Cross Infection | 1 | 2011 | 204 | 0.080 |
Why?
| | MicroRNAs | 1 | 2015 | 632 | 0.080 |
Why?
| | Vitamin B 12 Deficiency | 1 | 1988 | 74 | 0.080 |
Why?
| | Drug Discovery | 1 | 2009 | 123 | 0.080 |
Why?
| | Thrombelastography | 2 | 2022 | 142 | 0.080 |
Why?
| | Risk Factors | 8 | 2020 | 8949 | 0.080 |
Why?
| | Urinary Incontinence | 1 | 1988 | 61 | 0.080 |
Why?
| | Predictive Value of Tests | 3 | 2020 | 1850 | 0.080 |
Why?
| | Registries | 1 | 2016 | 1806 | 0.080 |
Why?
| | Biomarkers | 2 | 2015 | 3564 | 0.080 |
Why?
| | Interferon-gamma | 2 | 2008 | 735 | 0.080 |
Why?
| | Acute Lung Injury | 1 | 2011 | 278 | 0.080 |
Why?
| | Patient Readmission | 2 | 2010 | 630 | 0.080 |
Why?
| | Propionates | 2 | 2005 | 35 | 0.080 |
Why?
| | Platelet Count | 1 | 2007 | 81 | 0.080 |
Why?
| | Naphthalenes | 2 | 2005 | 41 | 0.070 |
Why?
| | Ventricular Function, Left | 2 | 2009 | 468 | 0.070 |
Why?
| | Likelihood Functions | 1 | 2007 | 136 | 0.070 |
Why?
| | Interleukin-7 Receptor alpha Subunit | 1 | 2006 | 11 | 0.070 |
Why?
| | Receptors, Interleukin-7 | 1 | 2006 | 26 | 0.070 |
Why?
| | Viral Load | 2 | 2021 | 405 | 0.070 |
Why?
| | Models, Statistical | 2 | 2015 | 632 | 0.070 |
Why?
| | Behavior Therapy | 1 | 1988 | 236 | 0.070 |
Why?
| | ROC Curve | 1 | 2007 | 466 | 0.070 |
Why?
| | Logistic Models | 3 | 2015 | 1894 | 0.070 |
Why?
| | Renal Dialysis | 1 | 2009 | 380 | 0.070 |
Why?
| | Heparin | 4 | 2005 | 230 | 0.060 |
Why?
| | Proportional Hazards Models | 2 | 2020 | 1123 | 0.060 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2013 | 2046 | 0.060 |
Why?
| | Clinical Trials as Topic | 1 | 2009 | 960 | 0.060 |
Why?
| | Ambulatory Care | 1 | 1988 | 481 | 0.060 |
Why?
| | Serine Endopeptidases | 1 | 2005 | 104 | 0.060 |
Why?
| | Chi-Square Distribution | 2 | 2011 | 523 | 0.060 |
Why?
| | Incidence | 2 | 2010 | 2413 | 0.060 |
Why?
| | Treatment Failure | 1 | 2005 | 340 | 0.060 |
Why?
| | Skilled Nursing Facilities | 1 | 1985 | 121 | 0.060 |
Why?
| | Hepatitis B Antibodies | 1 | 2003 | 10 | 0.060 |
Why?
| | Reperfusion Injury | 1 | 2006 | 272 | 0.060 |
Why?
| | Hepatitis B virus | 1 | 2003 | 25 | 0.060 |
Why?
| | Endoscopes, Gastrointestinal | 1 | 2003 | 12 | 0.060 |
Why?
| | House Calls | 1 | 1985 | 133 | 0.060 |
Why?
| | Kidney Failure, Chronic | 1 | 2009 | 516 | 0.060 |
Why?
| | Pilot Projects | 3 | 2009 | 1405 | 0.060 |
Why?
| | Continuity of Patient Care | 1 | 1985 | 260 | 0.060 |
Why?
| | Length of Stay | 3 | 2011 | 1027 | 0.060 |
Why?
| | Health Care Surveys | 1 | 2005 | 544 | 0.060 |
Why?
| | Aging | 1 | 1993 | 1672 | 0.050 |
Why?
| | Risk Assessment | 4 | 2015 | 3041 | 0.050 |
Why?
| | Colectomy | 1 | 2003 | 84 | 0.050 |
Why?
| | Sensitivity and Specificity | 1 | 2007 | 1783 | 0.050 |
Why?
| | Choledochostomy | 1 | 2022 | 7 | 0.050 |
Why?
| | Plasma | 2 | 2014 | 194 | 0.050 |
Why?
| | Anastomosis, Roux-en-Y | 1 | 2022 | 27 | 0.050 |
Why?
| | Clinical Protocols | 1 | 2003 | 234 | 0.050 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2006 | 694 | 0.050 |
Why?
| | Critical Care | 1 | 1985 | 486 | 0.050 |
Why?
| | DNA, Viral | 1 | 2003 | 351 | 0.050 |
Why?
| | Proof of Concept Study | 1 | 2021 | 46 | 0.050 |
Why?
| | Heterocyclic Compounds, 4 or More Rings | 1 | 2021 | 16 | 0.050 |
Why?
| | Sustained Virologic Response | 1 | 2021 | 33 | 0.050 |
Why?
| | Referral and Consultation | 1 | 1985 | 640 | 0.050 |
Why?
| | Feasibility Studies | 2 | 2004 | 747 | 0.050 |
Why?
| | Health Planning Councils | 1 | 2000 | 6 | 0.050 |
Why?
| | Government | 1 | 2000 | 9 | 0.050 |
Why?
| | Thrombosis | 1 | 2004 | 301 | 0.050 |
Why?
| | Mental Disorders | 1 | 1988 | 934 | 0.050 |
Why?
| | Blood Coagulation | 1 | 2022 | 202 | 0.050 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 1 | 2022 | 176 | 0.040 |
Why?
| | Muscular Atrophy | 1 | 2000 | 80 | 0.040 |
Why?
| | Adolescent | 6 | 2015 | 18339 | 0.040 |
Why?
| | Anticoagulants | 1 | 2004 | 554 | 0.040 |
Why?
| | Baltimore | 1 | 1999 | 42 | 0.040 |
Why?
| | Specialization | 1 | 2000 | 118 | 0.040 |
Why?
| | Cardiac Surgical Procedures | 1 | 2004 | 458 | 0.040 |
Why?
| | Nephrectomy | 1 | 2020 | 162 | 0.040 |
Why?
| | History, 20th Century | 1 | 2000 | 282 | 0.040 |
Why?
| | Hospitals, University | 1 | 1999 | 171 | 0.040 |
Why?
| | Streptokinase | 2 | 1997 | 11 | 0.040 |
Why?
| | Drug Administration Schedule | 1 | 2021 | 732 | 0.040 |
Why?
| | General Surgery | 1 | 2000 | 136 | 0.040 |
Why?
| | Postoperative Period | 2 | 2016 | 307 | 0.040 |
Why?
| | Linear Models | 1 | 2021 | 814 | 0.040 |
Why?
| | Withholding Treatment | 1 | 2018 | 67 | 0.040 |
Why?
| | Oxazines | 1 | 2018 | 25 | 0.040 |
Why?
| | Diagnosis-Related Groups | 1 | 1997 | 29 | 0.040 |
Why?
| | Patient Admission | 1 | 1999 | 177 | 0.040 |
Why?
| | Safety | 1 | 1999 | 304 | 0.040 |
Why?
| | Osteoporosis | 1 | 2000 | 226 | 0.040 |
Why?
| | Area Under Curve | 1 | 2018 | 292 | 0.040 |
Why?
| | Pyridones | 1 | 2018 | 119 | 0.040 |
Why?
| | Cause of Death | 2 | 2007 | 379 | 0.040 |
Why?
| | Tissue Plasminogen Activator | 2 | 1997 | 211 | 0.040 |
Why?
| | Lymphocytes | 1 | 2018 | 345 | 0.030 |
Why?
| | Attitude | 1 | 1998 | 230 | 0.030 |
Why?
| | Myocardial Reperfusion Injury | 1 | 1997 | 105 | 0.030 |
Why?
| | Data Collection | 1 | 1999 | 649 | 0.030 |
Why?
| | Fatigue | 1 | 2018 | 293 | 0.030 |
Why?
| | China | 1 | 2016 | 173 | 0.030 |
Why?
| | Piperazines | 1 | 2018 | 315 | 0.030 |
Why?
| | Phlebotomy | 1 | 2015 | 11 | 0.030 |
Why?
| | Family Characteristics | 1 | 2016 | 155 | 0.030 |
Why?
| | 2-Naphthylamine | 1 | 2014 | 7 | 0.030 |
Why?
| | Population | 1 | 2015 | 29 | 0.030 |
Why?
| | Half-Life | 1 | 2015 | 147 | 0.030 |
Why?
| | Uracil | 1 | 2014 | 35 | 0.030 |
Why?
| | Patient Reported Outcome Measures | 1 | 2017 | 251 | 0.030 |
Why?
| | Cyclopropanes | 1 | 2014 | 80 | 0.030 |
Why?
| | North America | 1 | 2015 | 264 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2016 | 478 | 0.030 |
Why?
| | Calcineurin Inhibitors | 1 | 2014 | 60 | 0.030 |
Why?
| | Social Class | 1 | 2016 | 217 | 0.030 |
Why?
| | Lactams, Macrocyclic | 1 | 2014 | 47 | 0.030 |
Why?
| | Biological Assay | 1 | 2015 | 122 | 0.030 |
Why?
| | Valine | 1 | 2014 | 76 | 0.030 |
Why?
| | Cadaver | 1 | 2015 | 327 | 0.030 |
Why?
| | Femoral Artery | 1 | 2015 | 176 | 0.030 |
Why?
| | Ritonavir | 1 | 2014 | 70 | 0.030 |
Why?
| | Sex Characteristics | 2 | 2015 | 667 | 0.030 |
Why?
| | Frail Elderly | 1 | 1994 | 105 | 0.030 |
Why?
| | Hepatocytes | 1 | 2014 | 204 | 0.030 |
Why?
| | DEAD Box Protein 58 | 1 | 2013 | 8 | 0.030 |
Why?
| | Leukocytes | 1 | 2014 | 283 | 0.030 |
Why?
| | Case-Control Studies | 2 | 2013 | 3142 | 0.030 |
Why?
| | Neutrophils | 1 | 2018 | 1136 | 0.030 |
Why?
| | Cholestasis | 1 | 2015 | 228 | 0.030 |
Why?
| | Patient Acceptance of Health Care | 1 | 1998 | 683 | 0.030 |
Why?
| | Nitriles | 1 | 2013 | 155 | 0.030 |
Why?
| | HIV-1 | 1 | 2018 | 773 | 0.030 |
Why?
| | Pain | 1 | 2018 | 735 | 0.030 |
Why?
| | Medicare Part B | 1 | 1991 | 6 | 0.030 |
Why?
| | Receptors, Immunologic | 1 | 2013 | 206 | 0.030 |
Why?
| | Prevalence | 1 | 2018 | 2321 | 0.020 |
Why?
| | Anxiety | 1 | 2018 | 844 | 0.020 |
Why?
| | Alcoholism | 1 | 2018 | 714 | 0.020 |
Why?
| | Emotions | 1 | 2016 | 494 | 0.020 |
Why?
| | Sulfonamides | 1 | 2014 | 444 | 0.020 |
Why?
| | Physical Examination | 1 | 1993 | 241 | 0.020 |
Why?
| | Cross-Over Studies | 1 | 2013 | 448 | 0.020 |
Why?
| | Chromatography, Liquid | 1 | 2013 | 352 | 0.020 |
Why?
| | Lumbar Vertebrae | 1 | 1993 | 214 | 0.020 |
Why?
| | Attitude of Health Personnel | 1 | 1998 | 988 | 0.020 |
Why?
| | Heart Transplantation | 1 | 1997 | 672 | 0.020 |
Why?
| | Insurance, Health, Reimbursement | 1 | 1991 | 88 | 0.020 |
Why?
| | Health Services Needs and Demand | 1 | 1992 | 251 | 0.020 |
Why?
| | Phosphorylation | 1 | 2015 | 1617 | 0.020 |
Why?
| | Body Weight | 1 | 2015 | 923 | 0.020 |
Why?
| | Tandem Mass Spectrometry | 1 | 2013 | 418 | 0.020 |
Why?
| | Research Design | 1 | 2016 | 960 | 0.020 |
Why?
| | Anti-Retroviral Agents | 1 | 2012 | 206 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2005 | 1928 | 0.020 |
Why?
| | Neoadjuvant Therapy | 1 | 2012 | 328 | 0.020 |
Why?
| | Erythrocytes | 1 | 2015 | 619 | 0.020 |
Why?
| | Pyrimidines | 1 | 2013 | 380 | 0.020 |
Why?
| | Depression | 1 | 2018 | 1134 | 0.020 |
Why?
| | Anemia, Pernicious | 1 | 1988 | 8 | 0.020 |
Why?
| | Obesity | 1 | 2022 | 2715 | 0.020 |
Why?
| | Urinary Incontinence, Stress | 1 | 1988 | 14 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 1993 | 1376 | 0.020 |
Why?
| | Biofeedback, Psychology | 1 | 1988 | 25 | 0.020 |
Why?
| | Fibrinogens, Abnormal | 1 | 2008 | 4 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2015 | 1588 | 0.020 |
Why?
| | CD24 Antigen | 1 | 2008 | 21 | 0.020 |
Why?
| | Vitamin B 12 | 1 | 1988 | 114 | 0.020 |
Why?
| | Academic Medical Centers | 1 | 2010 | 422 | 0.020 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2008 | 70 | 0.020 |
Why?
| | Societies, Medical | 1 | 1991 | 700 | 0.020 |
Why?
| | Myocardial Contraction | 1 | 2009 | 338 | 0.020 |
Why?
| | Genes, MHC Class II | 1 | 2007 | 72 | 0.020 |
Why?
| | Child | 2 | 2021 | 19026 | 0.020 |
Why?
| | Hospitalization | 1 | 1996 | 1778 | 0.020 |
Why?
| | Nurse Practitioners | 1 | 1988 | 106 | 0.020 |
Why?
| | Cytomegalovirus | 1 | 2007 | 144 | 0.020 |
Why?
| | Hospital Mortality | 1 | 2011 | 811 | 0.020 |
Why?
| | Internal Medicine | 1 | 1988 | 212 | 0.020 |
Why?
| | Stroke Volume | 1 | 2009 | 513 | 0.020 |
Why?
| | Organizational Affiliation | 1 | 1985 | 8 | 0.020 |
Why?
| | Immunity, Cellular | 1 | 2008 | 268 | 0.020 |
Why?
| | Dementia | 1 | 1988 | 207 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2016 | 4518 | 0.020 |
Why?
| | Waiting Lists | 1 | 2007 | 228 | 0.020 |
Why?
| | Pressure Ulcer | 1 | 1985 | 33 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 1985 | 209 | 0.020 |
Why?
| | Partial Thromboplastin Time | 1 | 2005 | 50 | 0.020 |
Why?
| | Ultrasonography | 1 | 2009 | 714 | 0.020 |
Why?
| | Fluid Therapy | 1 | 1985 | 129 | 0.020 |
Why?
| | Epitopes | 1 | 2006 | 438 | 0.020 |
Why?
| | Immunologic Memory | 1 | 2006 | 312 | 0.020 |
Why?
| | Alleles | 1 | 2007 | 824 | 0.020 |
Why?
| | Pneumonia | 1 | 1990 | 579 | 0.020 |
Why?
| | International Normalized Ratio | 1 | 2004 | 42 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2013 | 2238 | 0.010 |
Why?
| | Intraoperative Care | 1 | 2004 | 38 | 0.010 |
Why?
| | Blood Coagulation Tests | 1 | 2004 | 52 | 0.010 |
Why?
| | Canada | 2 | 1997 | 338 | 0.010 |
Why?
| | HIV Infections | 1 | 2018 | 2448 | 0.010 |
Why?
| | Physician's Role | 1 | 1985 | 200 | 0.010 |
Why?
| | Flow Cytometry | 1 | 2006 | 1071 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2014 | 4682 | 0.010 |
Why?
| | Drug Monitoring | 1 | 2004 | 185 | 0.010 |
Why?
| | Blood Pressure | 1 | 2009 | 1656 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2007 | 1237 | 0.010 |
Why?
| | Electrocardiography | 1 | 2005 | 555 | 0.010 |
Why?
| | Ischemia | 1 | 2005 | 370 | 0.010 |
Why?
| | Colorado | 1 | 2011 | 4175 | 0.010 |
Why?
| | Hemorrhage | 1 | 2005 | 606 | 0.010 |
Why?
| | Foundations | 1 | 2000 | 22 | 0.010 |
Why?
| | Organizational Objectives | 1 | 2000 | 74 | 0.010 |
Why?
| | Patient Education as Topic | 1 | 1985 | 696 | 0.010 |
Why?
| | Models, Biological | 1 | 2007 | 1698 | 0.010 |
Why?
| | Phenotype | 1 | 2006 | 2916 | 0.010 |
Why?
| | Education, Medical | 1 | 2000 | 232 | 0.010 |
Why?
| | Vascular Patency | 1 | 1997 | 98 | 0.010 |
Why?
| | Coronary Circulation | 1 | 1997 | 121 | 0.010 |
Why?
| | Child, Preschool | 1 | 2009 | 9441 | 0.010 |
Why?
| | Interviews as Topic | 1 | 1997 | 591 | 0.010 |
Why?
| | Regression Analysis | 1 | 1997 | 984 | 0.010 |
Why?
| | Institutionalization | 1 | 1992 | 12 | 0.010 |
Why?
| | Survival Rate | 1 | 1997 | 1714 | 0.010 |
Why?
| | Sex Factors | 1 | 1997 | 1764 | 0.010 |
Why?
| | Organizational Policy | 1 | 1991 | 70 | 0.010 |
Why?
|
|
Burton's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|